> Research Use Only. All compounds discussed in this article are research chemicals intended for laboratory use only. This content is for educational purposes. Not for human use, diagnosis, or treatment.
# Best Growth Hormone Research Peptides 2026: CJC-1295, Ipamorelin, Sermorelin & More
Growth hormone secretagogues are among the most studied peptide categories in biochemistry research. Spanning three distinct pharmacological classes — GHRH analogs, GH-releasing peptides (GHRPs), and oral secretagogues — they offer researchers a toolkit for probing the GH/IGF-1 axis with precision. This guide consolidates everything: how the classes differ, which compound best fits each research goal, how to stack them for synergistic effects, pricing benchmarks, and where to source them.
---
Why GH Secretagogues Matter in Research
Exogenous recombinant human growth hormone (rhGH) was the original tool for GH-axis research, but it bypasses the hypothalamic-pituitary regulatory loop entirely. GH secretagogues work differently: they stimulate the pituitary's own somatotrophs to release GH endogenously, preserving natural feedback inhibition (somatostatin, IGF-1 feedback). This makes them more relevant for studying:
- •Pulsatile GH secretion dynamics
- •Hypothalamic-pituitary axis (HPA) regulation
- •Age-related GH decline and somatopause models
- •Metabolic effects of physiologically-patterned GH release
- •Body composition and lipid metabolism in rodent models
The key distinction is where in the pathway each compound acts:
- •GHRH analogs (Sermorelin, CJC-1295, Tesamorelin) → bind GHRH receptors on pituitary somatotrophs
- •GHRPs (Ipamorelin, GHRP-2, GHRP-6, Hexarelin) → bind ghrelin receptor (GHSR-1a) on pituitary and hypothalamus
- •Combined stacks → hit both pathways simultaneously for synergistic GH pulse amplification
---
Quick Comparison Table: All 6 Core GH Peptides
| Compound | Class | Mechanism | Half-Life | Typical Research Dose | FDA Status | Best For |
|---|---|---|---|---|---|---|
| CJC-1295 (no DAC) | GHRH analog | GHRH receptor agonist | ~30 min | 100–300 mcg | Not approved | GHRH activation; stacking with GHRPs |
| CJC-1295 DAC | GHRH analog | GHRH receptor + albumin binding | 6–8 days | 1–2 mg/week | Not approved | Sustained GHRH stimulation |
| Sermorelin | GHRH analog | GHRH(1-29) receptor agonist | ~10–12 min | 200–500 mcg | Approved (compounding) | Pulsatile GHRH kinetics; short-t½ models |
| Tesamorelin | GHRH analog | Stabilized GHRH(1-44) | ~26 min | 1–2 mg | FDA-approved (Egrifta) | Metabolic/lipodystrophy research |
| Ipamorelin | GHRP | GHSR-1a agonist (selective) | ~2 hrs | 100–300 mcg | Not approved | Clean GH pulse; minimal off-target |
| GHRP-2 | GHRP | GHSR-1a agonist | ~1–1.5 hrs | 100–300 mcg | Not approved | High-potency GH stimulation |
| GHRP-6 | GHRP | GHSR-1a + appetite axis | ~1.5–2 hrs | 100–300 mcg | Not approved | Appetite/GH crosstalk studies |
| Hexarelin | GHRP | GHSR-1a + CD36 receptor | ~1 hr | 100–200 mcg | Not approved | Cardiac + GH dual-target research |
---
Best GHRH Analogs: CJC-1295 vs Sermorelin vs Tesamorelin
GHRH analogs bind the growth hormone-releasing hormone receptor (GHRHR) on anterior pituitary somatotrophs. They work "upstream" of GHRPs — stimulating the same pathway used by native GHRH. The key research differentiator is half-life, which determines the pulse pattern they produce.
Sermorelin — The Shortest, Most Physiological
Sermorelin is the truncated active fragment of native GHRH: GHRH(1-29)NH2. With a half-life of roughly 10–12 minutes, it produces sharp, short GH pulses that most closely mimic endogenous GHRH secretion kinetics.
Research strengths:
- •Closest to physiological GHRH pulse pattern
- •Ideal for studies examining GHRH receptor desensitization kinetics
- •FDA-regulated history (approved for pediatric GH deficiency diagnosis in the past) provides a richer clinical evidence base
- •Available from compounding pharmacies in some jurisdictions
Limitations for research:
- •Very short half-life requires precise timing protocols
- •Less practical for chronic exposure models without automated delivery
Key articles: Sermorelin Research Profile | Sermorelin Dosage Guide | Sermorelin vs CJC-1295 | Sermorelin vs Tesamorelin
---
CJC-1295 (No DAC) — The Research Workhorse
CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF) is Sermorelin with four amino acid substitutions that improve proteolytic stability. The result is a half-life of approximately 30 minutes — longer than Sermorelin but still producing pulsatile GH release when dosed intermittently.
Research strengths:
- •Balanced between physiological pulsatility and practical stability
- •Most widely used GHRH analog in research stacking protocols (paired with Ipamorelin)
- •Better characterized than Sermorelin in contemporary in vivo models
- •Predictable, reproducible GH pulse profiles at 100–300 mcg
Limitations:
- •No DAC version requires frequent dosing for chronic models (typically 3x daily)
- •Distinct from CJC-1295 DAC — they are pharmacokinetically different compounds; sourcing confusion is common
Key articles: CJC-1295 Research Profile | CJC-1295 Dosage Guide | CJC-1295 No DAC Guide
---
CJC-1295 DAC — Long-Acting GHRH Stimulation
CJC-1295 DAC adds a Drug Affinity Complex (DAC) technology that allows the peptide to covalently bind circulating serum albumin in vivo, extending its effective half-life to 6–8 days. This fundamentally changes the research model: instead of pulsatile GH stimulation, you get sustained, continuous GHRH receptor activation.
Research strengths:
- •Ideal for chronic IGF-1 elevation models without daily dosing
- •Useful for studying consequences of sustained (non-pulsatile) GHRH signaling
- •Practical for long-duration animal studies
Limitations:
- •Does NOT produce pulsatile GH — fundamentally different from short-acting GHRH analogs
- •Less relevant for studies requiring physiological pulse architecture
- •Potential for receptor desensitization with chronic use
---
Tesamorelin — The Clinically Validated Option
Tesamorelin is a stabilized GHRH(1-44) analog — the full-length native GHRH sequence with a trans-3-hexenoic acid group for stability. It's FDA-approved as Egrifta for HIV-associated lipodystrophy, giving it the most robust clinical evidence base of any GHRH analog.
Research strengths:
- •Extensive Phase III clinical trial data available
- •Validated biomarker endpoints (visceral fat reduction, IGF-1 normalization)
- •Half-life of ~26 minutes enables pulsatile protocols
- •Multiple metabolic endpoints: visceral adiposity, triglycerides, lean mass, cardiovascular risk markers
Best for: Metabolic syndrome models, HIV-associated lipodystrophy replication, body composition research
Key articles: Tesamorelin Research Profile | Tesamorelin Dosage Guide | Sermorelin vs Tesamorelin
> Full GHRH analog comparison: GHRH Analogs Compared: Sermorelin vs CJC-1295 vs Tesamorelin
---
Best GHRPs: Ipamorelin vs GHRP-2 vs GHRP-6 vs Hexarelin
GH-releasing peptides bind the ghrelin receptor (GHSR-1a) — the same target as the endogenous hormone ghrelin — to stimulate GH secretion from the pituitary. Unlike GHRH analogs, they also act at the hypothalamic level, suppressing somatostatin (GH inhibitor) while amplifying GH pulse amplitude.
The key research differentiator between GHRPs is receptor selectivity — specifically, how much off-target hormonal co-secretion they produce (cortisol, prolactin, ACTH).
Ipamorelin — Highest Selectivity, Cleanest GH Signal
Ipamorelin is the most receptor-selective GHRP available. It stimulates GH release with minimal or no elevation of cortisol, prolactin, or ACTH at standard research concentrations — a critical advantage when hormonal crosstalk would confound experimental results.
Research strengths:
- •Highest GHSR-1a selectivity of any GHRP
- •GH release without cortisol/prolactin co-secretion
- •Well-characterized dose-response curve in multiple species
- •The preferred GHRP for combination stacks (CJC-1295 + Ipamorelin)
- •Predictable, reproducible GH pulse profiles
Best for: Clean GH-axis research; stacking studies; any experiment where isolating GH effects matters
Key articles: Ipamorelin Research Profile | Ipamorelin Dosage Guide | Ipamorelin vs GHRP-2 | Ipamorelin vs GHRP-6 | Ipamorelin vs Sermorelin
---
GHRP-2 (Pralmorelin) — High Potency, Moderate Selectivity
GHRP-2 (also known as Pralmorelin) is the second-generation GHRP and one of the most potent GH-releasing compounds available for research. It produces more robust GH elevation than Ipamorelin at equivalent doses, but with measurable cortisol and prolactin co-secretion.
Research strengths:
- •Higher GH release magnitude than Ipamorelin
- •Studied as a clinical diagnostic tool for GH axis assessment (pralmorelin stimulation test)
- •Good for experiments requiring maximal GH stimulation
- •Moderate half-life (~1–1.5 hours)
Best for: GH stimulation studies where potency matters more than selectivity; diagnostic protocol modeling
Key articles: GHRP-2 Research Profile | GHRP-2 Dosage Guide | Ipamorelin vs GHRP-2
---
GHRP-6 — The Appetite Connection
GHRP-6 is the original GHRP used in research since the 1980s. It's a hexapeptide that stimulates potent GH release alongside pronounced appetite stimulation and significant cortisol/prolactin elevation — making it distinctly useful when appetite or ghrelin-axis crosstalk is part of the research question.
Research strengths:
- •Most extensively studied GHRP in the literature
- •Strongest appetite-stimulating effect of the class (ghrelin mimetic)
- •Useful for appetite regulation, metabolic, and obesity research
- •Rich mechanistic understanding available from 40+ years of study
Best for: Appetite/feeding behavior studies; ghrelin biology research; metabolic crossover studies
Key articles: GHRP-6 Research Profile | GHRP-6 Dosage Guide | Ipamorelin vs GHRP-6
---
Hexarelin — Potency + Cardioprotective Effects
Hexarelin is the most potent GHRP for GH release. Unlike other GHRPs, it also engages the CD36 scavenger receptor independently of GHSR, producing cardioprotective effects in myocardial models. This dual mechanism makes it uniquely valuable when cardiac biology is part of the research scope.
Research strengths:
- •Highest GH-releasing potency of the GHRP class
- •CD36-mediated cardioprotective effects (independent of GH axis)
- •Models for cardiac ischemia, myocardial remodeling, and heart failure
- •Studied in aging models for cardiac and GH-axis decline
Best for: Cardiac + GH dual-target research; maximal GH stimulation models; aging studies
Key articles: Hexarelin Research Profile | Hexarelin Dosage Guide | Hexarelin vs GHRP-6
> Full GHRP comparison: GHRPs Compared: GHRP-2 vs GHRP-6 vs Ipamorelin vs Hexarelin
---
Stack Combinations: Synergistic GH Research Protocols
One of the most important insights in GH secretagogue research is that GHRH analogs and GHRPs work through complementary, synergistic pathways. When combined, they produce GH release that exceeds the additive effects of either alone — sometimes by 3–5x compared to either compound individually.
The Gold Standard Stack: CJC-1295 + Ipamorelin
The CJC-1295 (no DAC) + Ipamorelin combination is the most widely used and best-characterized GH secretagogue stack in research.
How it works:
- •CJC-1295 binds GHRH receptors on pituitary somatotrophs → primes the cell for GH synthesis and release
- •Ipamorelin binds GHSR-1a → triggers GH pulse release AND suppresses hypothalamic somatostatin (the GH brake)
- •Combined: The GHRHR and GHSR pathways converge on cAMP/PKA signaling → synergistic GH release with physiological pulsatility
Research rationale: Studies in rodent models consistently show CJC-1295 + Ipamorelin produces larger GH pulses than either compound alone, with Ipamorelin's selectivity keeping hormonal co-secretion clean. This makes it the preferred combination for body composition, metabolic, and GH deficiency models.
Typical research protocol:
- •CJC-1295 (no DAC): 100–200 mcg
- •Ipamorelin: 100–300 mcg
- •Combined at same injection site, 2–3x daily
- •Evening administration (mimics natural nocturnal GH peak) preferred in circadian studies
Key articles: CJC-1295 + Ipamorelin Stack Guide | CJC-1295 vs Ipamorelin Comparison
---
Alternative Stack: CJC-1295 DAC + Ipamorelin
For chronic exposure models where daily injection frequency is a practical constraint, CJC-1295 DAC (1–2 mg, 1–2x weekly) combined with Ipamorelin (2–3x daily) provides sustained GHRH axis stimulation with regular GHRP-driven GH pulses. This approach sacrifices pulsatile GHRH architecture for experimental convenience.
GHRP-2 + Tesamorelin Stack
For metabolic research where GH potency and body composition endpoints are the primary goal, GHRP-2 + Tesamorelin offers both the clinical evidence base of Tesamorelin and the additional GH-releasing potency of GHRP-2. This combination is particularly relevant for visceral adiposity, lipid metabolism, and insulin sensitivity models.
---
How to Choose: Research Goal → Peptide Selection
| Research Goal | Recommended Compound | Why |
|---|---|---|
| Clean GH pulse, no hormonal noise | Ipamorelin alone | Highest GHSR selectivity |
| Maximum GH stimulation | Hexarelin or GHRP-2 | Highest potency in class |
| Appetite/feeding behavior | GHRP-6 | Strongest ghrelin-axis appetite effects |
| Cardiac + GH dual model | Hexarelin | Unique CD36 cardioprotective mechanism |
| GHRH kinetics, short t½ | Sermorelin | Closest to native GHRH pulse timing |
| GHRH kinetics, medium t½ | CJC-1295 (no DAC) | 30-min t½, pulsatile |
| Sustained IGF-1 elevation | CJC-1295 DAC | 6–8 day half-life |
| Metabolic/body composition | Tesamorelin | Largest clinical evidence base |
| Most-studied combination | CJC-1295 + Ipamorelin | Gold standard GHRH+GHRP stack |
| Chronic model, minimal injections | CJC-1295 DAC + Ipamorelin | Weekly GHRH + daily GHRP pulses |
---
Pricing Comparison
GH peptide pricing varies significantly by supplier quality tier (HPLC-tested vs. untested), vial size, and compound complexity. Here are representative 2026 market ranges based on verified supplier data:
| Compound | Low (untested) | Mid (COA available) | Premium (HPLC-verified) |
|---|---|---|---|
| Sermorelin (2 mg vial) | $12–18 | $20–30 | $35–50 |
| CJC-1295 no DAC (2 mg) | $15–22 | $25–40 | $40–60 |
| CJC-1295 DAC (2 mg) | $18–28 | $35–55 | $55–80 |
| Tesamorelin (2 mg) | $35–55 | $60–90 | $90–130 |
| Ipamorelin (2 mg) | $10–18 | $20–35 | $35–55 |
| GHRP-2 (2 mg) | $8–15 | $15–28 | $28–45 |
| GHRP-6 (5 mg) | $10–18 | $18–32 | $30–50 |
| Hexarelin (2 mg) | $15–25 | $28–45 | $45–70 |
> Live price comparison: Check real-time supplier pricing at /compare — updated regularly with current market rates across verified suppliers.
Important: In the GH peptide category, the gap between low and premium tiers reflects real purity differences. Third-party HPLC and mass spectrometry verification is especially important for GHRH analogs, where synthesis complexity makes contamination and truncation more common.
---
Top Suppliers for GH Research Peptides
The GH peptide category is one of the most competitively supplied in the research peptide market. Key quality markers to evaluate:
1. Third-party HPLC purity certificates (>98% for injectable-grade)
2. Mass spectrometry verification of molecular weight (critical for confirming CJC-1295 DAC vs. no DAC)
3. Lyophilization quality — GH peptides are particularly sensitive to moisture and temperature
4. Bacteriostatic water inclusion or availability for reconstitution
5. Cold shipping protocols — most GH peptides require cold chain for shipping
Browse verified suppliers with current inventory and pricing at /suppliers. Filter by compound to find which suppliers carry specific GH peptides with documented quality testing.
---
Research Safety Considerations
All compounds in this guide are research chemicals for use in qualified laboratory settings. Key considerations:
Peptide handling:
- •Reconstitute with bacteriostatic water (not sterile water) for extended stability
- •Store lyophilized peptides at -20°C; reconstituted solutions at 4°C, use within 30 days
- •Avoid repeated freeze-thaw cycles which degrade peptide integrity
GH secretagogue-specific notes:
- •GHRPs (especially GHRP-6 and GHRP-2) may cause hunger responses in animal models — relevant endpoint if not the study focus
- •Hexarelin may produce cardiac-related endpoints independently of GH — verify experimental design accounts for this
- •CJC-1295 DAC's 6–8 day half-life means dose accumulation in chronic models — plan washout periods accordingly
- •GHRH analogs require somatotroph function to work — models with hypophysectomy will show no response
Stacking considerations:
- •GHRH analog + GHRP combinations amplify GH release — start at lower doses in new models to establish baseline response
- •Tachyphylaxis (receptor desensitization) has been documented with chronic, high-frequency GHRP dosing — pulse protocols preferred over constant infusion
---
Frequently Asked Questions
Q: Which GH peptide is best for beginners in GH axis research?
CJC-1295 (no DAC) + Ipamorelin. The combination has the most published protocols, predictable dose-response curves, and the cleanest hormonal profile. Ipamorelin's selectivity makes it the most interpretable starting point.
Q: What's the difference between CJC-1295 and CJC-1295 DAC?
Completely different pharmacokinetics. CJC-1295 (no DAC / Mod GRF 1-29) has a ~30-minute half-life and produces pulsatile GH release. CJC-1295 DAC binds albumin and has a 6–8 day half-life, producing sustained (non-pulsatile) GHRH receptor activation. They're not interchangeable in research design. See: CJC-1295 No DAC Guide
Q: Is Sermorelin the same as CJC-1295?
No. Sermorelin is GHRH(1-29) with native sequence — shorter, faster-acting (~10-12 min half-life). CJC-1295 (no DAC) has 4 amino acid substitutions for stability, giving it a longer half-life. They bind the same receptor but with different kinetics. See: CJC-1295 vs Sermorelin Comparison
Q: Can you combine two GHRPs?
This is not a standard research protocol and provides no additional benefit — both bind the same GHSR-1a receptor and would compete for occupancy. Combine a GHRP with a GHRH analog for synergistic effects through separate pathways.
Q: Why use Tesamorelin instead of CJC-1295?
Tesamorelin has the largest clinical trial dataset of any GHRH analog (FDA-approved, Phase III trials in HIV lipodystrophy). If your research aligns with these validated endpoints — visceral fat, triglycerides, cardiovascular risk markers — Tesamorelin's evidence base is unmatched. CJC-1295 is more commonly used in general GH axis research where the metabolic-specific endpoint data isn't needed.
---
Related Resources
Comparison Guides
- •CJC-1295 vs Sermorelin: Research Comparison
- •Ipamorelin vs GHRP-2: GH Secretagogue Comparison
- •Ipamorelin vs GHRP-6: Research Comparison
- •Ipamorelin vs Sermorelin: GH Peptide Comparison
- •Hexarelin vs GHRP-6: Potency & Protocol Comparison
- •GHRPs Compared: Complete Research Guide
- •GHRH Analogs Compared: Sermorelin vs CJC-1295 vs Tesamorelin
- •Sermorelin vs Tesamorelin Comparison
Stack Guides
Dosage & Protocol Guides
- •CJC-1295 Dosage Guide
- •Ipamorelin Dosage Guide
- •Sermorelin Dosage Guide
- •Tesamorelin Dosage Guide
- •GHRP-2 Dosage Guide
- •GHRP-6 Dosage Guide
- •Hexarelin Dosage Guide
---
> Disclaimer: This article is for research and educational purposes only. All peptides discussed are research chemicals. This is not medical advice. Not for human use. Always follow applicable regulations in your jurisdiction.